255 320
Table 1 – Baseline characteristics of included studies
Study
Study design Period Population
Pt Nb
Mean/
median*
age (yr)
Mean/median*
PSA (ng/ml)
Mean/
median*
prostate
volume (cm
3
)
Magnetic
field
strength
MR pulse
sequences
Endorectal
coil
MR score
Definition of
positive MRI
Reference standard
Hauth (2015)
[25]Prospective 2011–2013 FB
94
64 (43–83)
9 (3–31)
51 (17–140)
1.5 T
T2WI/DWI/
DCEI/MRSI
No
PI-RADS v1
3
11–13-core TRUS
SBx + TBx
Lamb (2015)
[36]
Retrospective 2013–2013 FB & PNB
173
NR
NR
NR
1.5 T
T2WI/DWI
NR
NR
NR
12-core TRUS SBx
Brock (2015)
[15]
Prospective 2013–2014 PNB
168
64* (IQR 59–70) 9.2* (IQR 6.7–13.4) 55.4*
(IQR 42–80)
3 T
T2WI/DWI/DCEI
No
PI-RADS v1 NR
12/24-core TRUS
SBx + TBx
Grenabo Bergdahl
(2016)
[22]
Prospective 2013–2014 FB & PNB
83
69.3*
(IQR 69–69.6)
1.6* (IQR 0.9–2.7) NR
3 T
T2WI/DWI/
DCEI/MRSI
No
PI-RADS v1
3
10-core TRUS SBx + TBx
Wang (2015)
[58]
Prospective 2002–2009 FB & PNB
586
70 (26–91)
11.11* (0.02–9794) NR
1.5 T
T2WI/DWI/
DCEI/MRSI
Yes
PI-RADS v1
3
TRUS SBx
Pepe (2015)
[41]
Prospective 2011–2014 PNB
100
64*
8.6* (4.2–10)
NR
3 T
T2WI/DWI/
DCEI/MRSI
No
PI-RADS v1
4
TPBx + TBx
Panebianco (2015)
[39]
Prospective 2011–2014 FB (61.62%) &
PNB (38.34%)
925
(1140 total
cohort)
NR
NR
NR
3 T
T2WI/DWI/DCEI
Yes
PI-RADS v1 NR
14-core TRUS SBx;
45-core sat TPBx + TBx
Radtke (2015)
[46]
Prospective 2013–2013 FB (63.3%) &
PNB (36.7%)
294
64* (60–71)
7.3 (6.0)
47 (37.5)
3 T
T2WI/DWI/DCEI
No
PI-RADS v1 PI-RADS 2;
PI-RADS 3;
PI-RADS 4;
PI-RADS = 5;
24-core TPBx + TBx
Itatani (2014)
[27]
Retrospective 2004–2007 NR
193
68.9 (8.4);
70* (47–89)
11.8 (15.9);
7.9* (1.22–159)
NR
1.5 T
T2WI/DWI/DCEI
No
1–5 scale
(Likert)
3
12–14-core TRUS SBx
Porpiglia (2014)
[44]Prospective 2011–2013 PNB
170
65* (60–70)
6.9* (5.2–9.8)
42* (36–48)
1.5 T
T2WI/DWI/DCEI
Yes
Dichotomous Positive:
at least 2/3
MR seq. with
suspicious
findings
18–24-core TRUS SBx
(volume dependent)
Thompson (2014)
[56]
Prospective 2012–2013 FB (88%) &
PNB (12%)
150
62.4*
(IQR 55.0–66.4)
5.6* (IQR 4.5–7.5) 40*
(IQR 30–57)
1.5 T
(47%) &
3 T (53%)
T2WI/DWI/DCEI
No
PI-RADS v1
3
Median of 30 TPBx
(volume dependent)
Pokorny (2014)
[43]
Prospective 2012–2013 FB
223
63* (IQR 57–68) 5.3* (IQR 4.1–6.6) 41*
(IQR 30–59)
3 T
T2WI/DWI/DCEI
No
PI-RADS v1
3 (primary);
4
12-core TRUS SBx + TBx
Petrillo (2014)
[42]
Prospective 2009–2010 NR
136
NR
NR
NR
1.5 T
T2WI/DWI/MRSI
Yes
1–5 scale
(Likert)
3
12–16-core TRUS SBx
(volume + PSA dependent)
Javali (2014)
[29]Retrospective 2002–2011 NR
140
Control:
62.4 (10.5);
Study:
62.9 (12.1)
Control: 6.8 (2.3);
Study: 6.87 (2.6)
Control:
44 (14.2);
Study: 43 (18.4)
1.5 T
T2WI/MRSI
Yes
Dichotomous Cit/[Cho
+ Cr]
<
1.2
6-core TRUS SBx (
n
= 69),
12-core TRUS SBx
(
n
= 119)
Abd-Alazeez (2014)
[13]
Prospective 2007–2011 FB
129
62* (41–82)
5.8* (1.2–20)
40* (16–137)
1.5 & 3 T T2WI/DWI/DCEI
No
PI-RADS v1
3 (primary);
4
20-core TPBx
Abd-Alazeez (2014)
[12]
Retrospective NR
PNB
54
64* (39–75)
10* (2–23)
53* (19–136)
1.5 & 3 T T2WI/DWI/DCEI
No
PI-RADS v1
3 (primary);
4
20-core TPBx + TBx
(
n
= 15)
Matsuoka (2014)
[37]
Prospective 2007–2012 NR
135
67* (50–80)
7.0* (2.9–19.8)
25.4*
(12.7–90.2)
1.5 T
T2WI/DWI
No
1–5 scale
(Likert)
3
14-core TRUS SBX
Junker (2013)
[30]
Retrospective 2011–2013 PNB
73
62 (7.4)
7.0* (5.1–12.9)
45* (34–61)
3 T
T2WI/DWI/DCEI
No
PI-RADS
PI-RADS 10
and 11 for
all PCa
PI-RADS 13
for significant
PCa
10-core TRUS SBx + TBx
Busetto (2013)
[16]
Prospective 2010–2012 PNB
163
66.4 (5.3)
6.8 (1.6)
NR
3 T
T2WI/DWI/
DCEI/MRSI
Yes
NR
NR
10-core TRUS SBx + TBx
Rais-Bahrami
(2013)
[47]
Prospective 2007–2012 NR
583
61.3 (8.4)
9.9 (13.1)
NR
3 T
T2WI/DWI/
DCEI/MRSI
Yes
1–4 scale
(Likert)
2
3
12-core TRUS SBx + TBx
Kuru (2013)
[34]
Prospective 2010–2011 FB (51%) &
PNB (49%)
347
65.3 (42–82)
9.85 (0.5–104)
48.7 (9–180)
3 T
T2WI/DWI/DCEI
No
1–3 scale
(Likert)
2
12–36-core TRUS SBx
(volume dependent)
+ TBx
Ferda (2013)
[20]
Prospective NR
NR
164
(49–74)
(4.2–123)
NR
3 T
T2WI/DWI/
DCEI/MRSI
No
NR
In house
TRUS SBx
Ganie (2013)
[21]
NR
2007–2009 PNB
87
NR
NR
NR
1.5 T
T2WI/MRSI
Yes
MRSI Cho/
Cit ratio
In house
6 core TRUS SBx +
MRI TBx
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 2 5 0 – 2 6 6
255